Both clinical and preclinical studies using activators such as metformin, phenformin, and canagliflozin have shown encouraging results in specific cancer types, including HER2-positive breast cancer, colorectal cancer, and certain metabolic subtypes of lung cancer. This evidence concerns the gene ERBB2 and lung carcinoma.